Physician profile
Mark D Fleming
NPI 1235148404
$44,279.98
in general payments reported to CMS, 2019-2025
8 companies · $20K in 2025
The $20K reported for 2025 was more than what 94% of Hematology (Pathology) providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,700 · 2022: $11K · 2023: $3,163 · 2024: $6,000 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $29K · Food and Beverage: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,250.00 |
| Food and Beverage | $229.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| X4 Pharmaceuticals, INC. | $20,250.00 | 2025 | Xolremdi |
| Vertex Pharmaceuticals Incorporated | $19,500.00 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $3,200.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $500.00 | 2019 | |
| Dentsply Sirona INC | $447.61 | 2022 | |
| Innovation Technologies INC | $163.21 | 2023 | Irrisept |
| Tactile Systems Technology INC | $152.64 | 2022 | |
| Karl Storz Endoscopy-America | $66.52 | 2025 | Hopkins |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.